Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 17, 2010

BioFocus and Amgen Extend Drug and Target Discovery Collaboration Through 2012

  • BioFocus has extended its drug discovery collaboration with Amgen into 2012 and will earn $2.6 million in research fees over the first year of the new agreement. The new contract has also been expanded to incorporate the provision of target discovery and validation services by BioFocus in support of Amgen’s therapeutic programs. BioFocus could in addition receive access fee and success-based milestone payments.

    The firms’ collaboration to identify new molecules against a range of disease targets was initiated in 2002 and extended in 2006 and again in 2008. “With each extension, Amgen has expanded the range of services provided by BioFocus, with target discovery being included this time around,” remarks Chris Newton, Ph.D., svp at parent firm Galapagos' services division.

     



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »